Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 0.64 |
| ▸ | FLT3 | P36888 | 11/20 | 0.64 |
| ▸ | FLT4 | P35916 | 10/20 | 0.64 |
| ▸ | CSF1R | P07333 | 7/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 6/20 | 0.46 |
| ▸ | RAF1 | P04049 | 5/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099177 | 0.98 | PDGFRB (0.68) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1100705 | 0.93 | PDGFRB (0.75) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1099835 | 0.91 | PDGFRB (0.68) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1098941 | 0.90 | PDGFRB (0.63) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1099237 | 0.90 | PDGFRB (0.72) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1097810 | 0.88 | PDGFRB (0.62) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1099453 | 0.88 | PDGFRB (0.67) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1098860 | 0.87 | PDGFRB (0.73) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1099074 | 0.87 | FLT3 (0.84) | PDGFRBFLT3FLT4CSF1RCYP2C9 | |
| SCHEMBL1097685 | 0.87 | PDGFRB (0.65) | PDGFRBFLT3FLT4CSF1RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | PDGFRB 1056/4885FLT3 126/4885FLT4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.